Search

ProQR Announces Virtual Presentation at American Association for Pediatric Ophthalmology and Strabismus (AAPOS) 2021

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 02, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for

April 02, 2021
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

Press release

LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

October 18, 2019
ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares

Press release

LEIDEN, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

October 16, 2019
ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

Press release

LEIDEN, Netherlands and CAMBRIDGE, Mass., Oct.

October 15, 2019
ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference

Press release

LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

October 31, 2018
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

Press release

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

September 11, 2018
ProQR Announces Presentations at ECFS on Eluforsen for F508del Cystic Fibrosis and at CFF Research Conference

Press release

… RNA medicines for the treatment of severe genetic rare diseases, today announced upcoming presentations at the … designed to address the underlying cause of the disease by targeting the mRNA in CF patients that have the …

June 04, 2018
ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB

Press release

LEIDEN, the Netherlands, April 30, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V.

April 30, 2018
ProQR Announces Proposed Public Offering of Ordinary Shares

Press release

LEIDEN, the Netherlands, Nov.

November 13, 2017
ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021

Press release

LEIDEN, Netherlands & CAMBRIDGE, Mass., April 23, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for

April 23, 2021